About Zinc finger protein interacting with ribonucleoprotein K
Zinc finger protein interacting with ribonucleoprotein K (ZIK1) is a protein
from Homo sapiens identified by UniProt accession
Q3SY52, 487 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | Zinc finger protein interacting with ribonucleoprotein K |
| UniProt accession | Q3SY52 |
| Gene | ZIK1 |
| Organism | Homo sapiens |
| Length | 487 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (8)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.28
- hepatocellular carcinoma · score 0.03
- cancer · score 0.01
- neoplasm · score 0.01
- diffuse large B-cell lymphoma · score 0.00
- cervical squamous cell carcinoma · score 0.00
- Adenosquamous Carcinoma · score 0.00
- renal cell carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q3SY52-F1 | alphafold | PREDICTED | 65.28 | — |
Amino-acid sequence (487 residues)
MAAAALRAPT QVTVSPETHM DLTKGCVTFE DIAIYFSQDE WGLLDEAQRL LYLEVMLENF ALVASLGCGH GTEDEETPSD QNVSVGVSQS KAGSSTQKTQ SCEMCVPVLK DILHLADLPG QKPYLVGECT NHHQHQKHHS AKKSLKRDMD RASYVKCCLF CMSLKPFRKW EVGKDLPAML RLLRSLVFPG GKKPGTITEC GEDIRSQKSH YKSGECGKAS RHKHTPVYHP RVYTGKKLYE CSKCGKAFRG KYSLVQHQRV HTGERPWECN ECGKFFSQTS HLNDHRRIHT GERPYECSEC GKLFRQNSSL VDHQKIHTGA RPYECSQCGK SFSQKATLVK HQRVHTGERP YKCGECGNSF SQSAILNQHR RIHTGAKPYE CGQCGKSFSQ KATLIKHQRV HTGERPYKCG DCGKSFSQSS ILIQHRRIHT GARPYECGQC GKSFSQKSGL IQHQVVHTGE RPYECNKCGN SFSQCSSLIH HQKCHNT
Explore Zinc finger protein interacting with ribonucleoprotein K with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets